---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-019525"
form_type: "8-K"
ticker: null
cik: "0001642375"
company_name: "Guardion Health Sciences, Inc."
filed_at: "2024-05-15T23:59:59+00:00"
generated_at: "2026-06-01T23:14:41.545085+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Guardion Q1 net loss $4.7M; ISS backs Activ sale for $17.2M and dissolution plan

## Summary
- Q1 revenue $2.999M (-5.8% YoY); net loss $4.747M vs net income $0.533M prior year.
- ISS recommends stockholders vote FOR sale of Activ (Viactiv brand) and plan of liquidation.
- Activ sale for $17.2M cash; special meeting May 23, 2024; close targeted by June 30, 2024.
- Board unanimously recommends approval; expects liquidating distributions above recent stock price.
- Cash and equivalents $5.605M as of March 31, 2024; operating cash use improved to $754.6K.

## SEC filing metadata
- accession: 0001493152-24-019525
- form_type: 8-K
- cik: 0001642375
- company_name: Guardion Health Sciences, Inc.
- filed_at: 2024-05-15T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1642375/000149315224019525/0001493152-24-019525-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1642375/000149315224019525/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-019525
- JSON: https://secwatch.observer/filing/0001493152-24-019525.json
- Plain text: https://secwatch.observer/filing/0001493152-24-019525.txt

## Key facts
- Earnings Releases
  Guardion Health Sciences, Inc. reported the three months ended March 31, 2024 results: revenue $2,999,645, net income $(4,746,744).
  - Period: the three months ended March 31, 2024
  - Revenue: $2,999,645
  - Net income: $(4,746,744)
  - Result: reported results
  source text: the Special Meeting of its Stockholders to vote on these transactions. Financial highlights for the three months ended March 31, 2024 include the following: ● Total revenue was $2,999,645 for the three months ended March 31, 2024, as compared to $3,185,689 for the three months ended March 31, 2023, a decrease of $186,044 or 5.8%. Sales of the Viactiv ® product
  evidence_url: https://www.sec.gov/Archives/edgar/data/1642375/000149315224019525/0001493152-24-019525-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.